Roche Holding AG (RHHBY)
| Previous close | 41.81 |
| Open | 41.33 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 41.21 - 41.46 |
| 52-week range | 37.88 - 53.86 |
| Volume | |
| Avg. volume | 2,564,154 |
| Market cap | 285.464B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 18.69 |
| EPS (TTM) | 2.21 |
| Earnings date | N/A |
| Forward dividend & yield | 1.24 (3.12%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | 58.30 |
- Globe Newswire
Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
The BenchMark ULTRA PLUS tissue staining system, with optimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide high-quality, time-critical results to doctors and patients.With laboratory diagnostics involved in more than two-thirds of healthcare decision making, innovative laboratory solutions that enable an accurate and timely diagnosis are crucial to successful treatment.About 17 million new cases of cancer are diagnosed worldwide each ye
- Globe Newswire
Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics
The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment.Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.1 Many cancers can be cured if detected early and treated effectively.1The Roche Digital Pathology solution helps empower the digital transformation of pathology and enable bette
- Zacks
Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.
